These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 25158712)

  • 1. Demystifying the U.S. Food and Drug Administration: understanding regulatory pathways.
    Naghshineh N; Brown S; Cederna PS; Levi B; Lisiecki J; D'Amico RA; Hume KM; Seward W; Rubin JP
    Plast Reconstr Surg; 2014 Sep; 134(3):559-569. PubMed ID: 25158712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination products regulation at the FDA.
    Lauritsen KJ; Nguyen T
    Clin Pharmacol Ther; 2009 May; 85(5):468-70. PubMed ID: 19381151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Demystifying the U.S. Food and Drug Administration: I. Understanding agency structure and function.
    Levi B; Lisiecki J; Rubin P; D'Amico RA; Hume KM; Seward B; Cederna PS
    Plast Reconstr Surg; 2014 Jun; 133(6):1495-1501. PubMed ID: 24867731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of Food and Drug Administration regulation of drugs, biologics, and devices to be used for management of periodontal diseases.
    Tylenda CA; Weintraub M
    Ann Periodontol; 1997 Mar; 2(1):11-7. PubMed ID: 9151539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding physician responsibilities and limitations for drug and device off-label use.
    Sclafani AP
    Facial Plast Surg Clin North Am; 2007 May; 15(2):251-4, viii. PubMed ID: 17544942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation and Device Development: Tips for Optimizing Your Experience With the Food and Drug Administration.
    Brooks SS
    Tech Vasc Interv Radiol; 2017 Jun; 20(2):109-115. PubMed ID: 28673647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Aug; 73(164):49603-10. PubMed ID: 18958946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of drugs and devices: an evolution.
    Merrill RA
    Health Aff (Millwood); 1994; 13(3):47-69. PubMed ID: 7927161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 21st Century Cures Act: can the regulatory framework survive the "cures"?
    Osorio-de-Castro CG; Caetano R; Pepe VL
    Cad Saude Publica; 2015 Sep; 31(9):1807-10. PubMed ID: 26578005
    [No Abstract]   [Full Text] [Related]  

  • 10. Combination products: modernizing the regulatory paradigm.
    Hunter NL; Sherman RE
    Nat Rev Drug Discov; 2017 Aug; 16(8):513-514. PubMed ID: 28496147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA not NIH can speed new drugs.
    Miller HI
    Nature; 2011 Apr; 472(7342):169. PubMed ID: 21490657
    [No Abstract]   [Full Text] [Related]  

  • 12. The 21st Century Cures Act--Will It Take Us Back in Time?
    Avorn J; Kesselheim AS
    N Engl J Med; 2015 Jun; 372(26):2473-5. PubMed ID: 26039522
    [No Abstract]   [Full Text] [Related]  

  • 13. FDA reform plan edges closer to realisation.
    Marx V
    Lancet; 2012 Jun; 379(9832):2135. PubMed ID: 22690392
    [No Abstract]   [Full Text] [Related]  

  • 14. Clarification: 510k is premarket notification; it provides no patent or FDA approval.
    Burkhart CG
    J Drugs Dermatol; 2008 Feb; 7(2):105. PubMed ID: 18335644
    [No Abstract]   [Full Text] [Related]  

  • 15. The regulation of drugs and biologics: fifty years into the future.
    Kuhlik BN
    Food Drug Law J; 2000; 55(1):21-5. PubMed ID: 12269358
    [No Abstract]   [Full Text] [Related]  

  • 16. An overview of drug development in the United States and current challenges.
    Moore SW
    South Med J; 2003 Dec; 96(12):1244-55; quiz 1256. PubMed ID: 14696877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
    Harapanhalli RS
    Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Food and Drug Administration gets new tools to spur regulatory science.
    Norman B
    Health Aff (Millwood); 2012 Sep; 31(9):1919-22. PubMed ID: 22949438
    [No Abstract]   [Full Text] [Related]  

  • 19. Regulatory approval characteristics of antimicrobial versus non-antimicrobial products, 1984-2018: an evaluation of Food and Drug Administration flexibilities.
    Darrow JJ; Najafzadeh M; Stefanini K; Kesselheim AS
    Lancet Infect Dis; 2020 Jul; 20(7):e159-e164. PubMed ID: 32502431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Review of the Regulatory Framework for Initiation and Acceleration of Patient Access to Innovative Medical Products in Japan.
    Matsushita S; Tachibana K; Nakai K; Sanada S; Kondoh M
    Clin Pharmacol Ther; 2019 Sep; 106(3):508-511. PubMed ID: 30883696
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.